S-nitrosylating Agents Neutralize C. difficile Toxins
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments are inadequate for infections caused by Clostridium difficile, particularly those involving glucosylating toxins, as they fail to effectively address the pathogenic effects of these toxins on host cells.
Innovation Solution
Administration of S-nitrosylating agents, such as GSNO, in combination with inositol phosphates like InsP6, to S-nitrosylate pathogenic cysteine proteases, thereby inhibiting their activity and reducing the severity of infections by enhancing S-nitrosothiol action.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for C. difficile infections, then standard therapy is provided, but they fail to effectively address the pathogenic effects of glucosylating toxins on host cells
Solution Approach 1:
The patent converts the harmful effect of nitric oxide (which can cause tissue damage at high levels) into a beneficial therapeutic agent by using S-nitrosylating agents that selectively modify toxin cysteine residues, transforming a potentially harmful substance into a protective therapy that neutralizes toxins while minimizing off-target effects
Solution Approach 2:
The patent introduces S-nitrosylating agents as intermediary substances that mediate between the host and the toxin. These agents selectively modify the cysteine residues in toxin molecules, acting as a bridge that transfers the protective effect without directly confronting the toxin, thereby reducing cytotoxicity and inflammation
2Reliability
If S-nitrosylating agents are administered to neutralize toxins, then toxin activity is inhibited, but the mechanism of action requires precise targeting of cysteine residues
Solution Approach 1:
The patent applies local quality by directing the S-nitrosylation modification specifically to cysteine residues within the toxin molecules. The S-nitrosylating agents exhibit selective reactivity toward the thiol groups of cysteine residues in the toxin's active site, achieving precise local modification that disables toxin function without affecting other proteins or cellular components
Solution Approach 2:
The patent utilizes parameter changes by altering the chemical state of cysteine residues from reduced thiol groups to S-nitrosylated forms. This chemical transformation changes the reactivity and conformation of the toxin's cysteine protease domain, thereby inhibiting its catalytic activity and preventing toxin-mediated cellular damage
3Reliability
If inositol phosphates are used to enhance S-nitrosothiol action, then therapeutic effect is improved, but the combination therapy increases treatment complexity
Solution Approach 1:
The patent merges two therapeutic components - S-nitrosylating agents and inositol phosphates - into a combination therapy regimen. The inositol phosphates enhance the stability and activity of S-nitrosothiol intermediates, creating a synergistic effect that improves toxin neutralization. This combination approach integrates multiple mechanisms of action to achieve superior therapeutic outcomes compared to single-agent therapy
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination of S-nitrosylating agents and inositol phosphates effectively neutralizes Clostridium difficile toxins, reducing cytotoxicity and inflammation, and providing a therapeutic benefit in treating infections by inhibiting toxin-induced cell damage and inflammation.
Implementation Method 1
S-nitrosylation of pathologic cysteine proteases, such as autocatalytic exotoxins
Implementation Method 2
The clostridial glucosylating toxins and the multifunctional autoprocessing repeats-in-toxins (MARTX) share a common virulence mechanism for cell entry that represents a potential target for therapeutic intervention
Data Source
AI summary
Provided herein are methods for ameliorating the pathophysiology cysteine protease exotoxin comprising the step of administering to said individual an effective dose of an S-nitrosylating agent and an inositol phosphate or analog thereof.